Michael Erichsen, President and CEOAcross Latin America, immediate-release tablets remain a common format for many therapies, often delivering active ingredients rapidly and contributing to uneven gastrointestinal responses. In contrast, controlled-release formulation allows drug dispersion to be calibrated over time, shaping tolerability and consistency in clinical use. Unipharm has built its development strategy around that capability, combining broad manufacturing expertise with specialized experience in microgranule, or pellet-based, delivery systems.
From its Central American base, Unipharm operates one of the region’s most diversified pharmaceutical manufacturing platforms, producing tablets, hard capsules, injectables, liquids, semi-solids, dermatological products and sachets, while leveraging specialized partners for softgels. The breadth of dosage forms, described internally as the highest diversity in Central America, provides the operational foundation for its specialization in controlled-release pellet systems and supports lifecycle reformulation across multiple therapeutic categories.
“We aren’t solely interested in launching pharmaceutical products,” says Kirsten Erichsen, Portfolio Development and Market Strategy Manager. “We focus on how they release drugs, how they protect the patient, and how they perform consistently over time.”
How do multiparticulate pellet systems enhance drug release consistency?
Central to this approach is the company’s focus on multiparticulate systems composed of uniform microgranules, commonly referred to as pellets. These spherical particles carry the active pharmaceutical ingredient (API) and release it in a controlled manner once administered. The pellets are typically filled into capsules or sachets, or incorporated into other oral delivery formats, enabling immediate, delayed, or sustained release.
Compared with conventional single-unit tablets, multiparticulate pellet formulations offer several technical and clinical advantages. As each capsule or sachet contains multiple individual units, drug release can be more evenly distributed throughout the gastrointestinal tract, resulting in steadier plasma drug concentrations, reduced peak-related side effects, and a lower risk of dose dumping. For example, a 100 mg dose can be engineered to release in calibrated increments over several hours rather than delivering the full amount at once, reducing sudden peak exposure that often contributes to drowsiness or gastric irritation. This controlled-release behavior also helps discourage overconsumption when relief feels delayed, while protecting the gastrointestinal lining from sudden exposure to high drug levels. For pediatric and geriatric populations, the flexible dosing and ease of administration further improve adherence and treatment reliability.
How does Unipharm sustain product relevance through continuous reformulation?
The company applied similar discipline to its analgesic portfolio. An earlier immediate-release product was later reformulated into a modified-release multiparticulate system intended to prolong therapeutic effect while mitigating issues such as excessive peak exposure or gastrointestinal irritation.
Two long-standing product lines demonstrate how this approach translates into sustained relevance. Unipharm’s microencapsulated iron therapy, developed with a U.S. partner in the 1990s, has undergone continuous reformulation and evaluation to optimize absorption while reducing gastrointestinal side effects commonly associated with iron supplementation. Ongoing physician engagement across the region has informed adjustments in active combinations and release dynamics, helping the product maintain therapeutic credibility in price-sensitive markets.
-
We aren’t solely interested in launching pharmaceutical products. We focus on how they release drugs, how they protect the patient, and how they perform consistently over time.
The company applied similar discipline to its analgesic portfolio. An earlier immediate-release product was later reformulated into a modified-release multiparticulate system intended to prolong therapeutic effect while mitigating issues such as excessive peak exposure or gastrointestinal irritation.
“We don’t see formulation as a one-time innovation event,” says Michael Erichsen, president and CEO. “Each product evolves through physician feedback, patient experience, and regulatory realities in the markets we serve.”
How does regulatory coordination support pellet-based expansion across Latin America?
That same evolution extends beyond the laboratory. Scaling differentiated formulations across markets requires regulatory alignment, adapting dossiers, manufacturing documentation, and supporting studies to meet country-specific requirements. Unipharm manages compliance across eight regulatory authorities, serving markets from Guatemala to Ecuador and the Dominican Republic, along with engaging Mexican regulators. Experience navigating these varied approval pathways supports both lifecycle management of established products and the introduction of updated formulations across the region.
With that regulatory infrastructure in place, the company is expanding pellet-based development into gastroprotectants and advanced pain management therapies, where release kinetics directly shape tolerability and adherence. Investment in clinical validation and process refinement continues, reflecting regional demand for dosage forms that balance efficacy with safety.
Recognition has followed execution. Unipharm has been named a Top Pharmaceutical Microgranule Form Products Manufacturer for its leadership in controlled-release formulations and sustained contributions to therapeutic reliability across Latin America. The distinction reflects market acknowledgment of a formulation-first strategy and strengthens its position as a regional pharmaceutical partner delivering medicines engineered for improved performance in everyday clinical use.
Advancing Microgranule Drug Delivery Standards
Executives responsible for sourcing pharmaceutical microgranule form products face a familiar tension: conventional solid dosages remain cost efficient, yet they often fall short in controlling therapeutic release, minimizing gastrointestinal irritation and sustaining patient adherence. Generic tablets without advanced coating technologies may deliver the full active load too rapidly, increasing side effects or reducing duration of action. In analgesics, this can translate into short relief windows followed by repeated dosing. In iron supplementation, it can mean avoidable nausea that discourages compliance, particularly among pregnant patients. Competitive pressure in many markets has amplified this challenge, as low-cost alternatives crowd formularies without necessarily advancing therapeutic performance.
Microgranule and pellet-based systems respond to these limitations by shifting formulation strategy from simple compression to engineered release. Through extrusion and spheronization, active ingredients are incorporated into uniform spheres that can be designed for immediate, delayed or sustained release. Uniformity in size and structure contributes to more consistent dosing and mitigates dose dumping across the gastrointestinal tract. This design flexibility allows the same multiparticulate core to be filled into capsules or incorporated into alternative presentations that support pediatric and geriatric use. Smaller, evenly distributed units also offer the possibility of modified administration when swallowing is difficult, without compromising release control. Over time, these attributes can translate into steadier plasma levels, fewer peak-related adverse effects and more predictable patient response.
Formulation leaders evaluating partners in this field must look beyond baseline manufacturing capacity. Depth in controlled release design is central. A manufacturer’s ability to tailor release profiles to therapeutic intent, whether to prolong analgesic effect or to moderate iron exposure in sensitive populations, directly influences clinical performance and commercial differentiation. Continuous refinement of release kinetics based on physician feedback and patient experience is equally important, particularly in regions where generics dominate and differentiation depends on demonstrable patient benefit rather than price alone. Technical dialogue between manufacturer and medical community can strengthen this cycle of improvement and sustain relevance over decades.
Quality governance across multiple jurisdictions adds another layer of scrutiny. Multiparticulate systems introduce complexity in validation, documentation and change management. A supplier that can navigate diverse regulatory authorities while maintaining dossier consistency and managing product updates without disruption offers tangible strategic value. Experience coordinating submissions, supporting studies and production modifications across countries reduces launch risk, supports lifecycle management and protects continuity of supply in markets that may apply differing evidentiary standards.
Unipharm represents a distinctive case within this landscape. It operates one of Central America’s most diversified pharmaceutical manufacturing platforms, with pellet and microgranule technology positioned as a defined specialization. Its microgranulated iron formulation, developed in collaboration with a United States partner in the 1990s, has been continuously updated through medical consultation and supporting studies to enhance tolerability and release consistency. Its analgesic pellets have likewise undergone release modification to extend therapeutic effect while limiting gastrointestinal strain. The company manages regulatory engagement across eight authorities from Guatemala to the Dominican Republic, adapting documentation and study requirements to each jurisdiction. For executives prioritizing sustained release precision, regional regulatory fluency and sustained formulation refinement, Unipharm stands as a disciplined and strategically aligned partner in microgranule drug manufacturing.
...Read more
Pharmaceutical Microgranule Form Products Manufacturer Info
Q1
What led Luminova Pharma Group to be recognized among top pharmaceutical microgranule form product manufacturers?
Luminova Pharma Group has gained recognition as a Pharmaceutical Microgranule Form Products Manufacturer through its strong regional manufacturing presence and commitment to high-quality pharmaceutical production. Operating across multiple Latin American countries, the company delivers integrated healthcare solutions supported by advanced technology and GMP-certified facilities. Its ability to consistently produce safe and effective medications while maintaining international quality standards underpins its position in Pharmaceutical Microgranule Form Products Manufacturing.
Q2
How does Luminova Pharma Group differentiate its approach to pharmaceutical microgranule manufacturing?
An integrated manufacturing and innovation model defines how Luminova operates as a Pharmaceutical Microgranule Form Products Manufacturer. The company combines formulation development, production and commercialization within a single ecosystem, allowing better control over dosage forms such as microgranules. This approach supports improved drug stability, controlled release and patient-friendly administration, particularly for chronic and specialty treatments. Its emphasis on technology-driven production ensures consistent performance of microgranule-based formulations.
Q3
How does the company support pharmaceutical product development and distribution?
End-to-end capabilities strengthen Luminova’s role as a Pharmaceutical Microgranule Form Products Manufacturer. The company provides services spanning development, manufacturing, distribution and commercialization of pharmaceutical products. Through its network of “casas médicas” (medical divisions), it addresses acute, chronic and generic treatment segments, ensuring that products reach diverse patient populations efficiently. This vertically integrated structure allows seamless transition from formulation to market delivery.
Q4
What value do microgranule formulations bring to healthcare applications?
Enhanced drug delivery and patient compliance define the value of microgranule-based products developed by Luminova as a Pharmaceutical Microgranule Form Products Manufacturer. Microgranules enable controlled or modified release of active ingredients, improving therapeutic effectiveness while reducing dosing frequency. They also allow flexible administration formats, which can be particularly beneficial for pediatric and geriatric patients. These advantages make microgranule formulations increasingly important in modern pharmaceutical design.
Q5
What role do quality standards and certifications play in its manufacturing?
Strict adherence to international quality standards is central to Luminova’s Pharmaceutical Microgranule Form Products Manufacturer capabilities. The company complies with regional and global GMP frameworks, including standards aligned with WHO guidelines and regulatory authorities such as INVIMA and DIGEMID. These certifications ensure that manufacturing processes are validated, consistent and capable of delivering safe and effective pharmaceutical products across markets.
Q6
Why is Luminova Pharma Group relevant to current pharmaceutical manufacturing trends?
The growing demand for advanced drug delivery systems and accessible healthcare solutions has increased the importance of specialized manufacturers, and Luminova addresses this as a Pharmaceutical Microgranule Form Products Manufacturer. Its ability to combine scalable production, regional distribution and innovative dosage forms aligns with industry trends toward patient-centric therapies and improved bioavailability. By expanding access to high-quality medicines across Latin America, the company remains highly relevant to evolving global healthcare needs.
